Month: September 2021
-
MedTwos: Kate and Richard Vines
- 29 Sep 2021
Rare Cancers Australia founders Kate and Richard Vines give a rare insight into their remarkable partnership – how they met, and what makes it work.
Read more -
Sigma bids to acquire API
- 27 Sep 2021
API recommends to its shareholders to ‘progress the Sigma indicative proposal’, with the bid also subject to ACCC approval.
Read more -
Why Arrotex is best for Aussie mRNA
- 27 Sep 2021
CEO Dennis Bastas believes his local manufacturing proposal has a winning edge.
Read more -
Janssen CAR-T lands in Australia
- 27 Sep 2021
First of a new class of anti-BCMA therapies kicks off its HTA journey with an MSAC sub-committee appearance later this year.
Read more -
NMP review will finish on time: chair
- 27 Sep 2021
As the review committee chair commits to Hunt’s tight timeframe, MA’s Liz de Somer unveils an industry focus on NMP accountability.
Read more -
South African new boss for Sigma
- 27 Sep 2021
Vikesh Ramsunder has been head-hunted to replace Mark Hooper from February 2022.
Read more -
Movement on workplace vax plans
- 24 Sep 2021
Who is doing what in terms of pharma workplace vaccinations? Seventeen pharma companies provide an update on their policies and plans.
Read more -
Newcomer chases AZ in rare
- 24 Sep 2021
Having set up in Melbourne, this company has only one drug and it’s squarely targeting Alexion’s blockbuster.
Read more








